Does external beam radiation boost to pelvic lymph nodes improve outcomes in patients with locally advanced cervical cancer?

Caryn Wujanto 1*, Bok Ai Choo 1, David Tan 2, Arunachalam Ilancheran 3, Joseph Ng 3, Jeffrey J. H. Low 3, Liang Shen 4, Johann Tang 1 and Vicky Koh 1

Abstract
Background: Current recommendation for locally advanced cervical cancer includes pelvic external beam radiation therapy (EBRT) with concurrent chemotherapy followed by brachytherapy. Involvement of pelvic lymph nodes is an important prognostic factor in locally advanced cervical cancer and recurrence commonly occurs despite definitive treatment. To date, there is no standard guideline on whether an EBRT boost should be applied to involved pelvic lymph nodes. Our study aims to assess if pelvic EBRT boost would reduce recurrence, benefit survival, and affect associated toxicities.

Methods: We conducted a retrospective review of locally advanced cervical cancer cases treated with definitive treatment at our institution. Involvement of pelvic lymph nodes were assessed on CT, MRI (> 10 mm or suspicious features) or PET scan (SUVmax > 2.5). EBRT dose ranged from 45 to 50.4 Gy with nodal boost ranging from 3.6 – 19.8 Gy.

Results: Between 2008 to 2015, 139 patients with locally advanced cervical cancer underwent treatment. Sixty-seven patients had positive pelvic lymph nodes, of which 53.7% received a nodal boost. Five-year recurrence free survival was 48.6% with vs. 64.5% without nodal boost (P = 0.169) and 5-year overall survival in those with positive pelvic lymph nodes was 74.3% with vs. 80.6% without nodal boost (P = 0.143). There was no significant difference in toxicity with nodal boost.

Conclusions: EBRT boost to pelvic lymph nodes does not reduce recurrence or improve survival in locally advanced cervical cancer with lymph node involvement at diagnosis.

Keywords: Cervical cancer, Radiotherapy, Pelvic node, Radiation boost

Background
Cervical cancer is 4th most common cancer in females worldwide [1]. However, despite advances in treatment modalities and implementation of screening programs, it is still ranked 8th highest in overall cancer mortality rate in Singapore [2]. Current recommendations for locally advanced cervical cancer include pelvic external beam radiotherapy (EBRT) with concurrent cisplatin-containing chemotherapy regimen combined with intra-cavitary brachytherapy [3]. Involvement of pelvic lymph nodes is known to be one of the most important prognostic factors in cervical cancer [4]. In the recently revised FIGO staging, patients with positive pelvic lymph nodes have been included and classified as stage IIIC1 and those who also had positive para-aortic nodes were classified as stage IIIC2 [5]. Prior to this, FIGO staging did not formally classify lymph node involvement and to date there is no standardized guideline on external beam radiation boost to pelvic lymph nodes. However, previous retrospective studies have suggested some benefit of applying EBRT boost to pelvic lymph nodes as recurrence in pelvic lymph nodes is not uncommon following initial definitive radiotherapy [6–9]. This study aims to assess the benefit of external radiation boost to pelvic lymph nodes in patients with locally advanced cervical cancer with pelvic lymph node involvement at diagnosis.
beam radiation boost to pelvic lymph nodes in reducing local and distant recurrence rates, improving overall survival as well as its effect on radiotherapy associated toxicities.

**Methods**
A retrospective review of medical records of all patients who have undergone radical intent treatment with radiotherapy for locally advanced cervical cancer at our institution between 2008 to 2015 was performed following approval from the National Healthcare Group Domain Specific Review Board, Singapore. None of the patients included in this study had radical hysterectomy or pelvic lymph node dissection. Lymph nodes > 10 mm in diameter were interpreted as enlarged [10, 11]. Radiologically suspicious nodes (lymph nodes < 10 mm with round, irregular shape, or ill-defined edge, occurring as clusters or enhances with intravenous contrast) on computed tomography (CT) scan or magnetic resonance imaging (MRI) scan, and positron emission tomography (PET) avid nodes with a maximum standardized uptake value (SUVmax) > 2.5 were also considered to be involved.

**Radiotherapy**
The dose of EBRT ranged from 45 Gy to 50.4 Gy in 1.8 Gy daily fractions given over 25 to 28 fractions with 10 MV photons, 5 days a week. In patients receiving additional external beam radiation boost to pelvic lymph nodes, the dose ranged from 3.6 Gy to 19.8 Gy.

Following CT simulation and planning, radiotherapy treatment was carried out using a 4-field box, 3-dimensional conformal technique. All patients had to adhere to a bladder and bowel preparation protocol for the CT simulation and during the whole course of treatment. The clinical target volume (CTV) included the gross disease, cervix, proximal half of the vagina, parametrial tissues, internal and external iliac lymph node region, and the caudal part of the common iliac lymph node chain (up to the L5-S1 vertebrae junction). Treatment with an extended field (which included the para-aortic lymph nodes with the superior border at the level of the T11-T12 or T12-L1 vertebral junction) was administered to patients with clinically involved para-aortic or common iliac lymph nodes seen on CT, MRI, or PET-CT scans. The inguinal nodes were treated in patients with middle or lower vaginal involvement. In pelvic lymph nodes receiving nodal boost, the margins were 0.5 cm to the CTV and 0.5 to 1 cm to the planning target volume. Prescription of the radiation dose was based on the planning target volume and specified at the isocentre, with homogeneity requirements according to recommendations by the International Commission on Radiation Units and Measurements (ICRU-50). The beam arrangement comprised of a 4-field plan with an anterior-posterior beam arrangement and two lateral beams with multileaf collimators used as shielding.

All patients subsequently underwent image guided high dose rate intracavitary brachytherapy with iridium-192 source.

**Chemotherapy**
Patients receiving concurrent chemotherapy were given a standard dose of weekly cisplatin 40 mg/m².

**Post-treatment follow-up**
Following completion of radiotherapy treatment, patients were followed-up every week initially for the first 2 weeks, then 4 weeks later, and subsequently every 3 months for the first year, every 6 months for the 2nd year and annually thereafter. Patients were also regularly reviewed by other disciplines, including gynecologists and medical oncologists. Surveillance for recurrence consisted of history taking and clinical assessment including pelvic examination at every visit and re-assessment CT thorax, abdomen and pelvis with biopsy in the event that a recurrence is suspected. Patients were also assessed for toxicities during each visit using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 and managed as appropriate.

**Statistical analysis**
Overall survival (OS) was defined as time to death due to any cause and recurrence was based on diagnosis of first recurrence following completion of treatment. Estimation of OS and time to recurrence was derived using Kaplan-Meir analysis. Comparison of outcome was calculated using the Chi square test.

**Results**
A total of 139 patients were treated for cervical cancer from 2008 to 2015. At diagnosis, all patients were staged using the International Federation of Gynaecology and Obstetrics (FIGO) 2009 staging. The median follow-up was 25 months (range 1 to 106 months).

Sixty-two patients (44.6%) had no involvement of pelvic lymph nodes, 67 patients (48.2%) had lymph nodes that were enlarged (> 10 mm), radiologically suspicious or had a PET SUVmax > 2.5. Lymph node status was unclear in 10 patients. Squamous cell carcinoma (SCC) histology was most common in 76.2% (n = 106) of all patients. In 67 patients with positive pelvic nodes, 79.1% (n = 53) had SCC and in 62 patients with negative pelvic nodes, 85.5% (n = 53) had SCC (Table 1).

Out of 67 pelvic lymph node positive patients, approximately half (53.7%; n = 36) had received a boost to the pelvic lymph nodes and 46.3% (n = 31) did not receive boost to the pelvic lymph nodes. The mean size of positive pelvic lymph nodes that received boost was 19.6 mm and the mean size of positive pelvic lymph
nodes that did not receive boost was 16.0 mm. The median boost dose was 9 Gy (range of 3.6 Gy to 19.8 Gy) (Table 2). Out of 67 patients who had positive pelvic lymph nodes, 9 patients also had positive para-aortic lymph nodes at diagnosis and received extended field RT covering the involved para-aortic nodes as per our department protocol.

Concurrent cisplatin-based chemotherapy was given in 84.1% (n = 117) of all patients. In 67 patients with positive pelvic nodes, 89.6% (n = 60) received concurrent chemotherapy and in 62 patients with negative pelvic nodes, 75.8% (n = 47) received concurrent chemotherapy. In 36 patients with positive pelvic nodes who received nodal boost, 83.3% (n = 30) received concurrent chemotherapy and in 31 patients with positive pelvic nodes who had no nodal boost, 96.8% (n = 30) received concurrent chemotherapy (Table 2).

Of the 67 patients with positive pelvic lymph nodes, 4.5% (n = 3) had local recurrence only, 17.9% (n = 12) had distant metastases only, and 17.9% (n = 12) had both local and distant recurrence. Overall, 40.3% (n = 27) of patients with positive pelvic lymph nodes developed recurrence.

Table 1 Patient characteristics

|                  | Pelvic LN negative (n = 62) | Pelvic LN positive (n = 67) |
|------------------|-----------------------------|-----------------------------|
|                  | Nodal boost                 | No nodal boost              |
|                  | (n = 36)                    | (n = 31)                    |
| Age (Median years) | 67                          | 56                          | 56                          |
| Range (years)    | 36 to 95                    | 33 to 85                    | 37 to 82                    |
| Histology        |                             |                             |
| SCC              | 53                          | 28                          | 25                          |
| Adenocarcinoma   | 6                           | 4                           | 3                           |
| Adenosquamous    | 3                           | 2                           | 1                           |
| Small cell       | 0                           | 1                           | 0                           |
| Mucinous         | 0                           | 0                           | 1                           |
| Not available    | 0                           | 1                           | 1                           |
| FIGO stage*      |                             |                             |
| IA2              | 1                           | 0                           | 0                           |
| IB1              | 8                           | 5                           | 2                           |
| IB2              | 8                           | 2                           | 0                           |
| IIA              | 13                          | 5                           | 1                           |
| IIB              | 15                          | 9                           | 17                          |
| IIIA             | 0                           | 2                           | 2                           |
| IIIB             | 16                          | 13                          | 9                           |
| IVA              | 1                           | 0                           | 0                           |
| LN size (Median mm) | NA                        | 17                          | 15                          |
| Range (mm)       | NA                          | 7.7 to 38                   | 10 to 27                    |

(Abbreviations: SCC squamous cell carcinoma, LN lymph nodes. * International Federation of Gynaecology and Obstetrics (FIGO) 2009 staging.)

Table 2 Treatment characteristics of patients with positive pelvic lymph nodes

|                  | Nodal boost (n = 36) | No Nodal boost (n = 31) |
|------------------|----------------------|-------------------------|
| Concurrent chemotherapy | 30                   | 30                      |
| Boost technique |                       |                         |
| IMRT             | 6                    | -                       |
| 3D Conformal     | 16                   | -                       |
| AP/PA            | 11                   | -                       |
| Unknown          | 3                    | -                       |

EQD2 (EBRT)

|                  | Mean (Range Gy)       |
|------------------|-----------------------|
|                  | (n = 36)              |
|                  | (n = 31)              |
| Mean             | 57.3 Gy (Range 49.6 to 69.0 Gy) |
| Median           | 58.4 Gy (Range 49.6 to 69.0 Gy) | 50.63 Gy (Range 42.5 to 68.2 Gy) |
(local, distant or both) regardless of whether they received pelvic nodal boost. Comparison of recurrence rates in patients with positive pelvic lymph nodes who received nodal boost and those who did not receive nodal boost can be found on Table 3. Nine patients had positive para-aortic nodes and positive pelvic lymph nodes, of which the majority (77.8%, \( n = 7 \)) received pelvic nodal boost and all received extended field radiotherapy covering the para-aortic nodes. In 27 patients with positive pelvic lymph nodes who developed recurrence, 59.3% \( (n = 16) \) had pelvic LN size > 15 mm, 25.9% \( (n = 7) \) had suspicious features on radiological imaging, and 14.8% \( (n = 4) \) had pelvic LN size > 10 mm but less than 15 mm (Table 4).

The 5-year recurrence-free survival (RFS) was 82% for pelvic lymph node negative patients; 64.5% for pelvic lymph node positive patients with no nodal boost; and 48.6% for pelvic lymph node positive patients with nodal boost (Fig. 1). The 5-year overall survival (OS) rate was 93.4% for pelvic lymph node negative patients; 80.6% for positive pelvic lymph nodes with no nodal boost; and 74.3% for positive pelvic lymph nodes with nodal boost (Fig. 2). There was no significant difference in the development of both early and late toxicities including proctitis, cystitis and fracture of femoral head (Table 5).

**Discussion**

In this study, we identified 67 patients with positive pelvic lymph nodes, of which 53.7% \( (n = 36) \) received nodal boost to pelvic lymph node and 46.3% \( (n = 31) \) did not. We found that administering nodal boost to pelvic lymph nodes did not significantly improve 5-year RFS (48.6% with nodal boost vs. 64.5% without nodal boost, \( P = 0.169 \)). There was also no significant difference in OS in locally advanced cervical cancer with positive pelvic lymph nodes (74.3% with nodal boost vs. 80.6% without nodal boost, \( P = 0.143 \)). In fact, patients with positive pelvic lymph nodes who did not receive a nodal boost appeared to have fewer recurrences and better OS, however these were not statistically significant. In both groups of patients, recurrence tends to occur as distant metastases and a boost did not decrease local nodal recurrence. Recurrence rate in patients with positive pelvic lymph node who received concurrent chemoradiotherapy were comparable in those with nodal boost (33.3%, \( n = 12 \)) and those without nodal boost (35.5%, \( n = 11 \)).

There is a need for pelvic lymph node status to be uniformly assessed at the time of diagnosis and subsequent follow-up. Grigsby et al. [12] compared CT scan with fluorodeoxyglucose (FDG)-PET scan for lymph node staging in patients with cervical cancer and found FDG-PET to be superior to CT scan in detecting abnormal lymph nodes. FDG-PET would also be invaluable in detecting distant metastases which is significantly increased in lymph node positive patients [4, 7, 8, 13]. However, cost of FDG-PET scan may be a limiting factor in clinical practice. In our study, only 18.7% \( (n = 26) \) of all patients had PET scan as part of their staging mainly due to cost limitation.

The significance of pelvic lymph node involvement in indicating future recurrence has led to studies attempting to assess the benefit of a nodal boost to pelvic lymph nodes. However, results have been conflicting. In a retrospective study of 174 patients with locally advanced

| Table 3 | Outcome of treatment with or without pelvic nodal boost in lymph node (LN) positive patients |
|---------|-----------------------------------------------------------------------------------------------|
| Pelvic LN positive |                                                                                             |
| All \( (n = 67) \) |                                                                                             |
| Recurrence 27 (40.3%) | 16 (44.5%) | 11 (35.4%) |
| Local only 3 (4.5%) | 2 (5.6%) | 1 (3.2%) |
| Distant only 12 (17.9%) | 8 (22.2%) | 5 (16.1%) |
| Local and distant 12 (17.9%) | 6 (16.7%) | 5 (16.1%) |
| No recurrence 40 (59.7%) | 20 (55.5%) | 20 (64.6%) |
| Pelvic LN and para-aortic LN positive |                                                                                             |
| All \( (n = 9) \) |                                                                                             |
| Recurrence 6 (66.7%) | 4 (57.1%) | 2 (100%) |
| Local only 0 | 0 | 0 |
| Distant only 2 (22.2%) | 1 (14.2%) | 1 (50%) |
| Local and distant 4 (44.4%) | 3 (42.9%) | 1 (50%) |
| No recurrence 3 (33.3%) | 3 (42.9%) | 0 |

| Table 4 | Recurrence rate in patients with positive pelvic lymph nodes (LN) based on LN size |
|---------|------------------------------------------------------------------------------------|
| Size of pelvic LN | Recurrence \( (n = 27) \) |
| > 15 mm | 16 (59.3%) |
| 10 mm > LN size < 15 mm | 4 (14.8%) |
| Suspicious features | 7 (25.9%) |
cervical cancer by Ariga et al. [7], 33% (n = 58) had positive pelvic lymph nodes, of which the majority (91%) were given nodal boost and comparisons were then made against those who had negative pelvic nodes with no nodal boost. They demonstrated significant improvement in 5-year OS and disease-free survival rate for patients with positive and negative nodes (73% vs. 92%, P = 0.001; 58% vs. 84%, P < 0.001, respectively). Overall, they reported benefit of nodal boost in patients with positive pelvic lymph nodes as compared to those with negative pelvic lymph nodes who had no boost and suggested that nodal boost could be an alternative to surgical debulking of pelvic lymph nodes. In a small retrospective study involving 32 patients with pelvic lymph node positive cervical cancer who were treated with EBRT without boost irradiation to the pelvic lymph nodes, Yoshizawa et al. [14] reported that only 2 patients had failure in the pre-existing lymph nodes and that 95% of those who progressed did so with distant metastases. They therefore suggested that pelvic lymph node boost may not be necessary especially in view of the potential toxicities.

To the best of our knowledge, this is the first study that directly compares the outcome of EBRT boost to pelvic lymph nodes in patients with positive pelvic lymph nodes in locally advanced cervical cancer. While it may seem intuitive that a higher radiotherapy dose to gross disease should result in a better outcome, this is not evident in our study. One reason could be that cervical cancer is...
No funding was obtained for this study.

Not applicable.

Table 5 Toxicity

| Toxicity | Nodal boost (n = 36) | No Nodal boost (n = 31) |
|----------|----------------------|-------------------------|
| Proctitis G1 | 1 | 0 |
| G2 | 5 | 6 |
| Cystitis G2 | 1 | 2 |
| G3 | 2 | 1 |
| Femoral head Fracture | 1 | 1 |

Graded according to CTCAE version 4.0 (Proctitis Grade 1: Rectal discomfort, no intervention, Grade 2: Rectal symptoms, intervention indicated. Cystitis Grade 2: Moderate haematuria, Grade 3: Gross haematuria)

inherently radiosensitive and that EBRT with some dose contribution from the brachytherapy provides sufficient dose to achieve a cure. We also note that in our cohort, a slightly higher proportion of patients with positive pelvic lymph nodes who had no nodal boost received concurrent chemoradiotherapy (96.8% vs. 83.3%). Although the discrepancy was small and not statistically significant, future study design could perhaps aim to eliminate this discrepancy altogether so outcome can be more accurate given chemotherapy's role as a radiosensitizer.

In our cohort of patients with positive pelvic lymph nodes, approximately one third of patients developed recurrence despite definitive treatment. As resistance to radiotherapy have previously been suggested as a factor of treatment failure, predictive biomarkers to identify radiation resistance cells will be invaluable in selecting patients who will respond well to radiation while those with more resistance cells can be considered for additional treatment to improve treatment outcome. Unnecessary toxicities can also be spared in select groups [15].

Conclusion

Our results show that EBRT boost to pelvic lymph nodes did not improve OS nor reduce rate of local recurrence in patients with locally advanced cervical cancer. However, prospective studies are needed to establish evidence-based guidelines on EBRT boost to pelvic lymph nodes in locally advanced cervical cancer.

Abbreviations
CT: Computed tomography; CTCAE: Common terminology criteria for adverse events; CTV: Clinical target volume; EBRT: External beam radiation therapy; FDG: Fluorodeoxyglucose; FIGO: International Federation of Gynaecology and Obstetrics; ICRU-50: International Commission on Radiation Units and Measurements report 50; LN: Lymph node; MRI: Magnetic resonance imaging; OS: Overall survival; PET: Positron emission tomography; RFS: Recurrence free survival; SUVmax: Maximum standardized uptake value

Acknowledgements
Not applicable.

Funding
No funding was obtained for this study.

Availability of data and materials
The data set used in this study are available from the corresponding author on reasonable request.

Authors’ contributions
All the co-authors have contributed to the idea and design of this study. VK, CBA, DT, JL, JN, AI, JT participated in the patients treatment and follow-up. CW and VK collected the data. VK, CBA, DT, JT guided the study and contributed to the interpretation of the results. CW and VK drafted the manuscript with contribution from all co-authors. All co-authors have discussed, edited and approved this manuscript for submission. All authors read and approved the final manuscript.

Ethics approval and consent to participate
This retrospective study was performed following approval from the National Healthcare Group Domain Specific Review Board, Singapore. No consent was obtained in view of the retrospective nature of this study and all data used in the analysis of this study are fully anonymous.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interest.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Radiation Oncology, National University Cancer Institute, National University Hospital, NUHS Tower Block Level 7, Singapore 119228, Singapore. 2Department of Medical Oncology, National University Cancer Institute, National University Hospital, NUHS Tower Block, Level 7, Singapore 119228, Singapore. 3Division of Gynaecologic Oncology, National University Cancer Institute, National University Hospital, NUHS Tower Block, Level 12, Singapore 119228, Singapore. 4Biostatistics Unit, Yong Loo Lin School of Medicine, National University of Singapore, 21 Lower Kent Ridge Road, Singapore 119077, Singapore.

Received: 15 July 2018 Accepted: 9 April 2019
Published online: 25 April 2019

References
1. International Agency for Research on Cancer, World Health Organization. GLOBOCAN 2012: Cervical Cancer - Estimated Incidence, Mortality and Prevalence Worldwide in 2012. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. Accessed 5 Mar 2018.
2. Singapore Cancer Registry. Singapore Cancer Registry Interim Annual Report 2010-2014. https://www.nrd.gov.sg/docs/librariesprovider3/default-document-library/cancer-trends-2010-2014_interim-annual-report_final-public.pdf?sfrvsn=0. Accessed 5 Mar 2018.
3. National Comprehensive Cancer Network. NCCN Guidelines version 1.2018. https://www.nccn.org/professionals/physician_gls/pdf/cervical.pdf. Online. Accessed 5 Mar 2018.
4. Grigsby PW, Singh AK, Siegel BA, Dehdashti F, Rader J, Zoberi I. Lymph node control in cervical cancer. Int J Radiat Oncol Biol Phys. 2004;59:706–12.
5. Bhatla N, Berek J, Cuello M, et al. New revised FIGO staging of cervical cancer (2018). Abstract S020.2. Presented at the FIGO XXII World Congress of Gynecology and Obstetrics. Rio de Janeiro, Brazil, October 14–19, 2018. Int J Gynecol Obstet 2018;143(Suppl.1):22–36.
6. Wakatsuki M, Ohno T, Kato S, Ando K, Noda S, Kiyohara H, et al. Impact of boost irradiation on pelvic lymph node control in patients with cervical cancer. J Radiat Res. 2014;55:139–45.
7. Ariga T, Toita T, Kasuya G, Nagai Y, Inamine M, Kudaka W, et al. External beam boost irradiation for clinically positive pelvic nodes in patients with uterine cervical cancer. J Radiat Res. 2013;54:690–6.
8. Toita T, Nakano M, Higashi M, Sakumoto K, Kanazawa K. Prognostic value of cervical size and pelvic lymph node status assessed by computed tomography for patients with uterine cervical cancer treated by radical radiation therapy. Int J Radiat Oncol Biol Phys. 1995;33:843–9.
9. Beadle BM, Jhingran A, Yom SS, Ramirez PT, Eifel PJ. Patterns of regional recurrence after definitive radiotherapy for cervical cancer. Int J Radiat Oncol Biol Phys. 2010;76:1396–403.
10. Reinhardt MJ, Ehritt-Braun C, Vogelgesang D, Ihling C, Högerle S, Mix M, et al. Metastatic lymph nodes in patients with cervical cancer: detection with MR imaging and FDG PET. Radiology. 2001;218:776–82.
11. Kim SH, Kim SC, Choi BI, Han MC. Uterine cervical carcinoma: evaluation of pelvic lymph node metastasis with MR imaging. Radiology. 1994;190:807–11.
12. Grigsby PW, Siegel BA, Dehdashi F. Lymph node staging by positron emission tomography in patients with carcinoma of the cervix. J Clin Oncol. 2001;19:3745–9.
13. Kupets R, Thomas GM, Covens A. Is there a role for pelvic lymph node debulking in advanced cervical cancer? Gynecol Oncol. 2002;87:163–70.
14. Yoshizawa E, Koiwai K, Ina H, Fukazawa A, Sakai K, Ozawa T, et al. Outcomes of uterine cervical cancer patients with pelvic lymph node metastases after radiotherapy without boost irradiation of metastases. J Obstet Gynaecol Res. 2017;43:718–22.
15. Choo BA, Lee ZW, Zhao W, Wang X, Ng J, Low J, Deng LW. Biomarker discovery for early prediction of therapy resistance in cervical cancers. Ann Oncol. 2016;27:i94–i103.